Primary Sclerosing Cholangitis. A narrative review
DOI:
https://doi.org/10.17533/udea.iatreia.57Keywords:
cholangitis, sclerosing, cholangiocarcinoma, cholestasis, ulcerative colitis, colorectal neoplasms, liver transplantationAbstract
Primary sclerosing cholangitis (PSC) is a rare, chronic liver pathology characterized by inflammation and fibrosis of the bile ducts, whose evolution can lead to cirrhosis, portal hypertension and end-stage liver disease. Its etiology is unknown, but it has been related to genetic and autoinflammatory factors. In addition, it has a very close relationship with inflammatory bowel disease. Its clinical presentation is nonspecific, the main symptoms are pruritus and fatigue.
The standard test for diagnosis is magnetic resonance cholangiopancreatography (MRCP), where an annular aspect is observed caused by short multifocal stenoses with alternating normal or dilated segments. Currently, there is no pharmacological treatment that can prolong the survival without liver transplantation in PSC. Symptomatic treatment is warranted, especially for pruritus. The only curative treatment that is currently available is liver transplantation, although there is a risk of recurrence of the disease. The monitoring of intestinal inflammatory disorders (IID), malignancy and metabolic bone disease in these patients is very important. It has been seen that some factors, such as early diagnosis, are good prognosis for the disease.
Downloads
References
(1) Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391(10139):2547-59. DOI: 10.1016/S0140-6736(18)30300-3.
(2) Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review. J Hepatol. 2012;56(5):1181-8. DOI: 10.1016/j.jhep.2011.10.025.
(3) Kumar A, Wheatley D, Puttanna A. Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management. Clin Med Insights Gastroenterol. 2016;9:25–9. DOI 10.4137/CGast.S38451.
(4) Visseren T, Darwish Murad S. Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation. Best Pract Res Clin Gastroenterol. 2017;31(2):187-98. DOI 10.1016/j.bpg.2017.04.004.
(5) Silveira MG, Lindor KD. Primary sclerosing cholangitis. Can J Gastroenterol. 2008;22(8):689-98. DOI 10.1155/2008/824168.
(6) Parés A. Colangitis esclerosante primaria: diagnóstico, pronóstico y tratamiento. Gastroenterol. Hepatol. 2011;34(1):41-52. DOI 10.1016/j.gastrohep.2010.02.006.
(7) Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110(5):646-59. DOI: 10.1038/ajg.2015.112.
(8) Fattahi MR, Malek-Hosseini SA, Sivandzadeh GR, Sivandzadeh GR, Safarpour AR, Lankarani KB, et al. Clinical Course of Ulcerative Colitis After Liver Transplantation in Patients with Concomitant Primary Sclerosing Cholangitis and Ulcerative Colitis. Inflamm Bowel Dis 2017;23(7):1160-7. DOI 10.1097/MIB.0000000000001105.
(9) Boonstra K, Weersma R, van Erpecum K, Rauws E, Spanier B, Poen A et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045-55. DOI 10.1002/hep.26565.
(10) Lazaridis K, LaRusso N. Primary Sclerosing Cholangitis. N Engl J Med. 2016;375(12):1161-70. DOI 10.1056/NEJMra1506330.
(11) Fricker ZP, Lichtenstein DR. Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. Dig Dis Sci. 2019;64(3):632-642. DOI 10.1007/s10620-019-05484-y.
(12) Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012;18 (1):1-15. DOI 10.3748/wjg.v18.i1.1.
(13) Horsley-Silva J, Carey E, Lindor K. Advances in primary sclerosing cholangitis. Lancet Gastroenterol Hepatol. 2016;1(1):68-77. DOI 10.1016/S2468-1253(16)30010-3.
(14) European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Cholestatic Liver Diseases. J Hepatol. 2009;51(2):237-267. DOI 10.1016/j.jhep.2009.04.009.
(15) Vries A, Jane M, Blokzi H, Weersma RK. Distinctive inflammatory bowl disease phenotype in primaru sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956-71. DOI 10.3748/wjg.v21.i6.1956.
(16) Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz S. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features. Gut Liver. 2018;12(1):17-29. DOI 10.5009/gnl16510.
(17) Zheng H, Jiang X. Increased Risk of Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Meta-Analysis of 16 Observational Studies. Eur J Gastroenterol Hepatol. 2016;28(4):383-90. DOI 10.1097/MEG.0000000000000576.
(18) Selvaraj EA, Culver EL, Bungay H, Bailey A, Chapman RW, Pavlides M, et al. Envolving role of magnetic resonance techniques in primary sclerosing cholangitis. World J Gastroenterol. 2019;25(6):644-58. DOI 10.3748/wjg.v25.i6.644.
(19) Tanaka A. IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis. Gut Liver. 2019;13(3):300-07. DOI 10.5009/gnl18085.
(20) Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kowdley KV, Kim RW, et al. Diagnosis and Management of Primary Biliary Cholangitis. Am J Gastroenterol. 2019;114(1):48-63. DOI 10.1038/s41395-018-0390-3.
(21) Sridhar S, Vaneet J. Primary Sclerosing Cholangitis: A Clinical Update. EMJ, 2019;4(3):101-10.
(22) Chapman MH, Thorburn D, Hirschfield GM, Webster GG, Rushbrook SM, Graeme, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356-78. DOI 10.1136/gutjnl-2018-317993.
(23) Lindstrom L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduce levels of
alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11(7):841-6. DOI 10.1016/j.cgh.2012.12.032.
(24) Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Ann Hepatol. 2016;15(2):246-53. DOI 10.5604/16652681.1193721.
(25) Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129(5):1464-72. DOI 10.1053/j.gastro.2005.08.017.
(26) Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808-14. DOI 10.1002/hep.23082.
(27) Williamson K, Chapman R. New Therapeutic Strategies for Primary Sclerosing Cholangitis. Semin Liver Dis. 2016;36(1):5-14. DOI 10.1055/s-0035-1571274.
(28) Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379-86. DOI 10.1002/hep.20457.
(29) Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ. Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score. Dig Dis Sci. 2016;61(10):3037-44. DOI 10.1007/s10620-016-4250-y.
(30) Tabibian JH, Weeding E, Jorgensen RA, Petz L, Keach JC, Talwalkar JA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis—a pilot study. Aliment Pharmacol Ther. 2013;37(6):604-12. DOI 10.1111/apt.12232.
(31) Damman JL, Rodriguez EA, Ali AH, Buness CW, Cox KL, Carey EJ, et al. Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018;47(7):886-95. DOI 10.1111/apt.14540.
(32) Bajaj JS, Hays RA. Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis. Am J Gastroenterol. 2019;114 (7):1027-29. DOI 10.14309/ajg.0000000000000191.
(33) Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011;140(1):180-8. DOI 10.1053/j.gastro.2010.10.014.
(34) Gomi H, Takada T, Hwang TL, Akazawa K, Mori R, Endo I, et al. Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis. J Hepatobiliary Pancreat Sci. 2017;24(6):310-8. DOI 10.1002/jhbp.452.
(35) Gomi H, Solomkin JS, Schlossberg D, Okamoto K, Takada T, Strasberg SM, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3-16. DOI 10.1002/jhbp.518.
(36) Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660-78. DOI 10.1002/hep.23294.
(37) Funga BM, Tabibianb JH. Biliary endoscopy in the management of primary sclerosing cholangitis and its complications. Liver Res. 2019;3(2):106-17. DOI 10.1016/j.livres.2019.03.004.
(38) Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, Stiehl A, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51(1):149-55. DOI 10.1016/j.jhep.2009.01.023.
(39) European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol. 2017;66(6):1265-81. DOI 10.1016/j.jhep.2017.02.013.
(40) Gluck M, Cantone NR, Brandabur JJ, Patterson DJ, Bredfeldt JE, Kozarek RA. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42(9):1032-39. DOI 10.1097/MCG.0b013e3181646713.
(41) Martin E, Levy C. Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis. Semin Liver Dis. 2017;37(4):305-13. DOI 10.1055/s-0037-1608655.
(42) Brandsaeter B, Friman S, Broome U, Isoniemi H, Olausson M, Bäckman L, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scan J Gastroenterol. 2003;38(11):1176-83. DOI 10.1080/00365520310006009.
(43) Cholongitas E, Shusang V, Papatheodoridis GV, Marelli L, Manousou P, Rolando N et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14(2):138-43. DOI 10.1002/lt.21260.
(44) Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15(3):330-40. DOI 10.1002/lt.21679.
(45) Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, La-Russo NF, Porayko MK et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29(4):1050-6. DOI 10.1002/hep.510290427.
(46) Taghavi SA, Eshraghian A, Niknam R, Sivandzadeh GR, Bagheri K. Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2018;12(6):575-84. DOI 10.1080/17474124.2018.1473761.
(47) Ali AH, Tabibian JH, Nasser-Ghodsi N, Lennon RJ, De-Leon T, Borad MJ et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology. 2018;67(6):2338-51. DOI /10.1002/hep.29730.
(48) Wannhoff A, Brune M, Knierim J, Weiss KH, Rupp C, Gotthardt DN. Longitudinal analysis of CA19-9 reveals individualized normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2019;49(6):769-78. DOI 10.1111/apt.15146.
(49) Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis a comprehensive review. J Hepatol. 2017;67(6):1298-323. DOI 10.1016/j.jhep.2017.07.022.
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Universidad de Antioquia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
